Digital Storytelling and Breastfeeding Education

August 10, 2026 updated by: Zübeyde Ceylan

Evaluatıon of the Effect of Breastfeedıng Educatıon Delıvered Usıng Dıgıtal Storytellıng Methods on Mothers' Breastfeedıng Success and Breastfeedıng Self-effıcacy

The aim of this study was to evaluate the effect of breastfeeding education provided using the digital storytelling method on mothers' breastfeeding self-efficacy and breastfeeding success. The study was conducted using a quasi-experimental pretest-posttest control group design. A total of 216 postpartum women participated in the study, including 108 women in the intervention group and 108 women in the control group. The intervention group received breastfeeding education based on the digital storytelling method, while the control group received routine breastfeeding education provided in the hospital. Breastfeeding self-efficacy and breastfeeding success were evaluated after the intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Breastfeeding is one of the most important factors affecting maternal and infant health. Educational interventions may improve breastfeeding outcomes by increasing mothers' confidence and knowledge regarding breastfeeding practices. Digital storytelling is an innovative educational approach that combines visual, audio, and narrative elements to improve learning experiences.

This study was conducted to evaluate the effectiveness of digital storytelling-based breastfeeding education on breastfeeding self-efficacy and breastfeeding success among postpartum women. The study was carried out between September 2024 and December 2025 in the postpartum unit of Etlik City Hospital. Participants were assigned to either an intervention group receiving digital storytelling-based breastfeeding education or a control group receiving standard breastfeeding education.

Data were collected using a Demographic Information Form, the Breastfeeding Self-Efficacy Scale-Short Form, and the Bristol Breastfeeding Assessment Tool. The findings of the study are expected to contribute to the development of innovative breastfeeding education strategies and support evidence-based maternal health practices.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
216

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Ankara
      • Ankara, Ankara, Turkey (Türkiye), 06010
        • Etlik City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population consisted of postpartum women hospitalized in the postpartum unit of Etlik City Hospital between September 2024 and December 2025. A total of 216 postpartum women participated in the study.

Description

Inclusion Criteria:

  • Women aged 18 years and older
  • Postpartum women
  • Able to communicate in Turkish
  • Literate
  • Healthy mother and healthy newborn
  • Voluntarily agreed to participate in the study

Exclusion Criteria:

  • Refusal to participate in the study
  • Mothers with conditions preventing breastfeeding
  • Mothers with severe maternal or neonatal complications
  • Communication problems preventing participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Experimental Group
Participants received breastfeeding education prepared using the digital storytelling method. Breastfeeding self-efficacy and breastfeeding success were evaluated after the intervention.
Control Group
Participants received routine breastfeeding education provided by the hospital. Breastfeeding self-efficacy and breastfeeding success were evaluated after the intervention.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Breastfeeding Self-Efficacy
Time Frame: Within 24 hours after breastfeeding education
The Breastfeeding Self-Efficacy Scale is a 33-item scale originally developed by Dennis in 1999. Subsequently, in 2003, she developed the Short Form of the Breastfeeding Self-Efficacy Scale by reducing it to 14 items. It is a 5-point Likert-type scale. Scores range from a minimum of 14 to a maximum of 70; higher scores indicate greater breastfeeding self-efficacy. Dennis states that the scale is suitable for use during the postpartum period. Aluş Tokat, Okumuş, and Dennis conducted a reliability and validity study of the Turkish version of the short-form scale; they determined it to be suitable for the Turkish culture, finding a Cronbach's alpha value of 0.86.
Within 24 hours after breastfeeding education

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Breastfeeding Success
Time Frame: 5 and 12 hours after breastfeeding education
It is a scale developed by Ingram et al. in 1998 to assess the breastfeeding process. Its Turkish validity and reliability were established by Dolgun et al. in 2018, yielding a Cronbach's alpha value of 0.77. The scale evaluates breastfeeding across four main categories: positioning, latching, observable sucking ability, and maternal comfort. Each criterion is scored on a scale of 0 to 2, resulting in a total possible score of 8. Higher scores indicate greater breastfeeding success. The BBAT is designed for use in breastfeeding support and education programs, serving as a tool for healthcare professionals and mothers to assess the breastfeeding process.
5 and 12 hours after breastfeeding education

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Zübeyde Ceylan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 30, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 18, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ZC-DSB-2024-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings